The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo
Abstract
BACKGROUND: Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A cream formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in repigmentation in a phase 2 trial involving adults with vitiligo. METHODS: We conducted two phase 3, double-blind, vehicle-controlled trials (Topical Ruxolitinib Evaluation in Vitiligo Study 1 [TRuE-V1] and 2 [TRuE-V2]) in North America and Europe that involved patients 12 years of age or older who had nonsegmental vitiligo with depigmentation covering 10% or less of total body-surface area. Patients were randomly assigned in a 2:1 ratio to apply 1.5% ruxolitinib cream or vehicle control twice daily for 24 weeks to all vitiligo areas on the face and body, after which all patients could apply 1.5% ruxolitinib cream through week 52. The primary end point was a decrease (improvement) of at least 75% from baseline in the facial Vitiligo Area Scoring Index (F-VASI; range, 0 to 3, with higher scores indicating a greater area of facial depigmentation), or F-VASI75 response, at week 24. There were five key secondary end points, including improved responses on the Vitiligo Noticeability Scale. RESULTS: A total of 674 patients were enrolled, 330 in TRuE-V1 and 344 in TRuE-V2. In TRuE-V1, the percentage of patients with an F-VASI75 response at week 24 was 29.8% in the ruxolitinib-cream group and 7.4% in the vehicle group (relative risk, 4.0; 95% confidence interval [CI], 1.9 to 8.4; P<0.001). In TRuE-V2, the percentages were 30.9% and 11.4%, respectively (relative risk, 2.7; 95% CI, 1.5 to 4.9; P<0.001). The results for key secondary end points showed superiority of ruxolitinib cream over vehicle control. Among patients who applied ruxolitinib cream throughout 52 weeks, adverse events occurred in 54.8% in TRuE-V1 and 62.3% in TRuE-V2; the most common adverse events were application-site acne (6.3% and 6.6%, respectively), nasopharyngitis (5.4% and 6.1%), and application-site pruritus (5.4% and 5.3%). CONCLUSIONS: In two phase 3 trials, application of ruxolitinib cream resulted in greater repigmentation of vitiligo lesions than vehicle control through 52 weeks, but it was associated with acne and pruritus at the application site. Larger and longer trials are required to determine the effect and safety of ruxolitinib cream in patients with vitiligo. (Funded by Incyte; TRuE-V1 and TRuE-V2 ClinicalTrials.gov numbers, NCT04052425 and NCT04057573.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use
LEWIS-JONES, M. S., & FINLAY, A. Y. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1995.tb16953.x · Cited by 1,051
Human skin pigmentation: Melanocytes modulate skin color in response to stress
Costin, G.-E., & Hearing, V. J. (2007) · The FASEB Journal · doi:10.1096/fj.06-6649rev · Cited by 976
Quintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843
Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients
van den Boorn, J. G., Konijnenberg, D., Dellemijn, T. A. M., Wietze van der Veen, J. P., Bos, J. D., Melief, C. J. M., Vyth-Dreese, F. A., & Luiten, R. M. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.32 · Cited by 543
New discoveries in the pathogenesis and classification of vitiligo
Rodrigues, M., Ezzedine, K., Hamzavi, I., Pandya, A. G., & Harris, J. E. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.10.048 · Cited by 476
Self-citationHarris, J. E., Harris, T. H., Weninger, W., John Wherry, E., Hunter, C. A., & Turka, L. A. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.463 · Cited by 389
Self-citationMechanisms of melanocyte death in vitiligo
Chen, J., Li, S., & Li, C. (2021) · Medicinal Research Reviews · doi:10.1002/med.21754 · Cited by 307
Vitiligo: A focus on pathogenesis and its therapeutic implications
Bergqvist, C., & Ezzedine, K. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15743 · Cited by 277
Self-citationPsychosocial effects of vitiligo: a systematic literature review
Ezzedine, K., Eleftheriadou, V., Jones, H., Bibeau, K., Kuo, F. I., Sturm, D., & Pandya, A. G. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00631-6 · Cited by 276
Self-citationVitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy
Boniface, K., Seneschal, J., Picardo, M., & Taïeb, A. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8622-7 · Cited by 272
Self-citationRuxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
Rosmarin, D., Pandya, A. G., Lebwohl, M., Grimes, P., Hamzavi, I., Gottlieb, A. B., Butler, K., Kuo, F., Sun, K., Ji, T., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30609-7 · Cited by 271
Self-citationPhototherapy for Vitiligo: A Systematic Review and Meta-analysis
Bae, J. M., Jung, H. M., Hong, B. Y., Lee, J. H., Choi, W. J., Lee, J. H., & Kim, G. M. (2017) · JAMA Dermatology · doi:10.1001/jamadermatol.2017.0002 · Cited by 242
Liu, L. Y., Strassner, J. P., Refat, M. A., Harris, J. E., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.05.043 · Cited by 241
Self-citationYones, S. S., Palmer, R. A., Garibaldinos, T. M., & Hawk, J. L. M. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.5.578 · Cited by 207
Regazzetti, C., Joly, F., Marty, C., Rivier, M., Mehul, B., Reiniche, P., Mounier, C., Rival, Y., Piwnica, D., Cavalié, M., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.335 · Cited by 194
Self-citationWang, X. X., Wang, Q. Q., Wu, J. Q., Jiang, M., Chen, L., Zhang, C. F., & Xiang, L. H. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14416 · Cited by 191
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib
Rothstein, B., Joshipura, D., Saraiya, A., Abdat, R., Ashkar, H., Turkowski, Y., Sheth, V., Huang, V., Au, S. C., Kachuk, C., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.02.049 · Cited by 189
Self-citationTreatment Outcomes of Topical Calcineurin Inhibitor Therapy for Patients With Vitiligo
Lee, J. H., Kwon, H. S., Jung, H. M., Lee, H., Kim, G. M., Yim, H. W., & Bae, J. M. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.0696 · Cited by 126
Joshipura, D., Alomran, A. M., Zancanaro, P. Q., & Rosmarin, D. M. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.02.023 · Cited by 87
Self-citationInterfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo.
Rashighi, M., & Harris, J. E. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.11.36 · Cited by 86
Self-citationMartins, C. P., Migayron, L., Drullion, C., Jacquemin, C., Lucchese, F., Rambert, J., Merhi, R., Michon, P., Taïeb, A., Rezvani, H. R., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.09.015 · Cited by 85
The humanistic burden of vitiligo: a systematic literature review of quality‐of‐life outcomes
Picardo, M., Huggins, R. H., Jones, H., Marino, R., Ogunsola, M., & Sénéschal, J. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18129 · Cited by 85
Acral lesions of vitiligo: why are they resistant to photochemotherapy?
Esmat, S. M., El‐Tawdy, A., Hafez, G., et al. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04215.x · Cited by 81
Quality of life in people with vitiligo: a systematic review and meta-analysis
Morrison, B., Burden-Teh, E., Batchelor, J. M., Mead, E., Grindlay, D., & Ratib, S. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15933 · Cited by 70
Sanclemente, G., García, J. G., Tobón, J. J. Z., et al. (2008) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2008.02839.x · Cited by 64
Repigmentation in vitiligo: position paper of the Vitiligo Global Issues Consensus Conference
Gan, E. Y., Eleftheriadou, V., Esmat, S. M., Hamzavi, I. H., Passeron, T., Böhm, M., Anbar, T. S., Goh, B. K., Lan, C.-C. E., Lui, H., et al. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12561 · Cited by 60
Self-citationFerrari, S. M., Fallahi, P., Santaguida, G., Virili, C., Ruffilli, I., Ragusa, F., Centanni, M., & Antonelli, A. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.006 · Cited by 39
Tsai, H., Lu, J.-W., Chen, L.-Y., & Chen, T. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11040279 · Cited by 38
Hamzavi, I. H., Rosmarin, D. M., Harris, J. E., Pandya, A. G., Lebwohl, M., Gottlieb, A. B., Butler, K. A., Kuo, F. I., Sun, K., & Grimes, P. E. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.05.047 · Cited by 36
Self-citationChang, H., Hsu, Y., & Huang, Y. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.108 · Cited by 35
Cited by
Skin Pigmentation Types, Causes and Treatment—A Review
Thawabteh, A. M., Jibreen, A., Karaman, D., Thawabteh, A., & Karaman, R. (2023) · Molecules · doi:10.3390/molecules28124839 · Cited by 233
Evaluation of Facial Vitiligo Severity with a Mixed Clinical and Artificial Intelligence Approach
Hillmer, D., Merhi, R., Boniface, K., Taieb, A., Barnetche, T., Seneschal, J., & Hagedorn, M. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.07.014 · Cited by 37
Self-citationPathogenesis of Vitiligo: Integrating Immune and Non-Immune Cell Crosstalk
Inoue, S. (2026) · The Journal of Dermatology · doi:10.1111/1346-8138.70067 · Cited by 3
Predictors of Response to Topical Ruxolitinib in Non‐segmental Vitiligo: A Narrative Review
Bettolini, L., Maione, V., Carugno, A., Fratton, Z., Errichetti, E., Crivellari, M., Cartocci, A., Maronese, C. A., Venturini, M., Zerbinati, N., et al. (2026) · Australasian Journal of Dermatology · doi:10.1111/ajd.70090 · Cited by 3
Metadata
- Authors
- Rosmarin, D., Passeron, T., Pandya, A. G., Grimes, P., Harris, J. E., Desai, S. R., Lebwohl, M., Ruer-Mulard, M., Seneschal, J., Wolkerstorfer, A., Kornacki, D., Sun, K., Butler, K., & Ezzedine, K.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-10-20
- Volume
- 387
- Issue
- 16
- Pages
- 1445-1455
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4306839892
- Cited by
- 316
- References
- 32
- FWCI
- 23.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.